Drug reference
bulevirtide
Entry inhibitor · Antiviral, Hepatitis D agent
Entry inhibitorAntiviral, Hepatitis D agent
CDSCO approved
EXCRETION
—
not curated
INTERACTIONS
—
none in our sources
PREGNANCY
—
not curated
Mechanism
Bulevirtide is an entry inhibitor that irreversibly binds to sodium taurocholate cotransporting peptide (NTCP), preventing viral entry into hepatocytes.
Indications
Hepatitis D (regulatory approval in Europe)Investigational for HBV (phase III development)
Dosing
- Adult
- Daily subcutaneous injection
Related guidelines
Ask House about bulevirtide
Continue into a citation-backed clinical answer with the drug context already attached.
Textbook-sourced·Sources: Goodman & Gilman 14e, Harrison 22e·Updated: 2026-05-10